-

Tom De Weerdt Joins PCI Pharma Services as Senior Vice President, Chief Financial Officer, Former CFO Serge Dupuis Retiring

PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced that Tom De Weerdt has joined the Company as Senior Vice President (SVP), Chief Financial Officer (CFO). Mr. De Weerdt succeeds Serge Dupuis, who is retiring.

“Serge has been an outstanding CFO for PCI, helping lead the Company through the past two years of unprecedented growth,” said Salim Haffar, CEO, PCI Pharma Services. “I am very pleased to welcome Tom De Weerdt to PCI as our new SVP, CFO. Tom is an established leader who brings transformational change, growth and efficiency to organizations. Tom’s depth of global and executive financial expertise will allow PCI to continue its trajectory of growth, financial strength and global expansion so we can broaden the impact of our purpose and mission to deliver medicines to patients around the world.”

Mr. De Weerdt joins PCI with over 20 years of experience in financial leadership roles at large, global corporations. In his previous role, he was EVP and CFO of the global, private-equity-held Mauser Packaging Solutions. Before that, he held a number of senior leadership positions, including EVP and CFO at Surgical Care Affiliates; VP Finance and Corporate Controller at Mead Johnson Nutrition; and VP Finance and CFO for Whirlpool Corporations’ Europe, Middle East and Africa division.

“PCI is the partner of choice for healthcare companies around the globe, because of its uncompromising focus on quality and operational excellence, while providing an industry-leading client experience. I am honored and excited by the opportunity to join this great organization in its next phase of growth,” said Mr. De Weerdt. “PCI is always looking to the future, propelled by innovation and a strong commitment to developing world-class talent — and these are some of the attributes that drew me to the Company. I look forward to working with the PCI teams and the board, as we continue to deliver the best solutions to solve our clients’ most challenging problems.”

Mr. De Weerdt holds an MBA in finance and accounting from The University of Chicago Booth School of Business; a master’s in applied information technology from VLEKHO in Brussels, Belgium; and a master’s in commercial engineering, marketing concentration, from Katholieke Universiteit Leuven, Belgium. He is a licensed CPA and serves on the board of Over the Rainbow, a not-for-profit organization providing affordable, assisted-living housing for people with physical disabilities, and is an Executive Partner at Executive Coaching Connections.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com.

Contacts

Bailey Watroba, WE Communications
bwatroba@we-worldwide.com / +1-617-234-4110

PCI Pharma Services


Release Versions

Contacts

Bailey Watroba, WE Communications
bwatroba@we-worldwide.com / +1-617-234-4110

Social Media Profiles
More News From PCI Pharma Services

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases

PHILADELPHIA--(BUSINESS WIRE)--Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI), a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility. ALD-102 is currently in preclinical trials a...

PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne and San Diego

PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced that three new state-of-the-art automated sterile fill-finish machines at its San Diego and Melbourne facilities are now fully operational. The innovative machinery from Cytiva can be used to fill various sterile medications into vials and syringes for small-to-mid scale client needs. The equipment, paired with PCI’s end-to-end services, accelera...

PCI Pharma Services Expands Biologics Leadership with new Center of Excellence Facility in the Midwest

PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced plans for a new 200,000-square-foot facility in Rockford, Illinois to enhance the organization’s capacity in injectable drug-device combination product assembly of both biologics and small molecules. Building on PCI’s leadership in this space with its Philadelphia Biotech Center of Excellence, the new facility is the second expansion building off...
Back to Newsroom